PharmExec Blog

Viehbacher Exits Sanofi

Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO yesterday. Chairman Serge Weinberg will replace Viehbacher on an interim basis. Read More »

Posted in Europe, Global, leadership, Strategy | Tagged , | Leave a comment

Orphan Drug Market to Reach $176 Billion by 2020, Says Report

By 2020, orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to EvaluatePharma’s Orphan Drug Report 2014. At 11 percent, this growth is set to be more than double the 5 percent growth rate of the overall prescription market, excluding generics. Read More »

Posted in Global, Orphan Drugs | Tagged , , , | Leave a comment

NHL Treatment Market Boom Will Be Hindered in EU

The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research. Read More »

Posted in Europe, R&D, Strategy | Tagged , , , , , , | Leave a comment

Gilead and Yale Extend Sequencing Initiative

After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years. The original agreement was forged in 2011 and can be renewed for up to 10 years. Read More »

Posted in R&D, Strategy, Technology | Tagged , | Leave a comment

Legislators Urge Added Incentives for Ebola Drug Development

Leading Senators are proposing legislation to add Ebola to the list of diseases eligible for priority review vouchers from the Food and Drug Administration as an incentive for biopharma companies to invest in treatments for this deadly disease. The priority review voucher (PRV) program for neglected tropical diseases (NTDs) currently applies to 16 deadly conditions that afflict millions of people in developing countries, but are rare or “neglected” in the U.S. and Europe. Ebola is not on FDA’s list, as it was not considered a serious threat when the program was established in 2007, but that obviously has changed. Read More »

Posted in healthcare, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta